Deerfield Management’s United Therapeutics UTHR Stock Holding History

Deerfield Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248M	Hold	457,000	–	–	2.58%	8
2026 Q1	$271M	Buy	457,000 +31,007	+7%	+$15.4M	3.2%	6
2025 Q4	$208M	Hold	425,993	–	–	2.65%	8
2025 Q3	$179M	Sell	425,993 -114,633	-21%	-$38.6M	2.73%	5
2025 Q2	$155M	Buy	540,626 +265,400	+96%	+$79.3M	2.82%	9
2025 Q1	$84.8M	Buy	+275,226	New	+$94.3M	1.68%	17

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Deerfield Management's UTHR Position: Q2 2026 in Review

Deerfield Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 457,000 shares worth $248M. The position accounts for 2.58% of the portfolio, ranked #8.

Deerfield Management first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $271M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Deerfield Management held 457,000 shares of United Therapeutics worth $248M as of Q2 2026.
Deerfield Management left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 2.58% of Deerfield Management's portfolio in Q2 2026, its #8 holding.
Deerfield Management first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
Deerfield Management's United Therapeutics position peaked at $271M in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.